FIELD: cosmetic treatment.
SUBSTANCE: method for carrying out cosmetic treatment in a human patient with inter-brow wrinkles includes injecting a total dose from approximately 0.2 ng to approximately 20 ng of botulinum neurotoxin of serotype E, where the total dose is divided into five approximately equal doses of botulinum neurotoxin of serotype E, and the specified approximately equal doses are intramuscularly injected into following muscles: the procerus muscle, left medial corrugator, right medial corrugator, left lateral corrugator and right lateral corrugator; and the beginning of the clinical effect of cosmetic treatment occurs within 24 hours after the injection of botulinum neurotoxin of serotype E. Other options for cosmetic treatment in a human patient with inter-brow wrinkles are also disclosed.
EFFECT: group of inventions provides a reduction in inter-brow wrinkles.
18 cl, 1 tbl, 9 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| LIQUID COMPOSITION OF NEUROTOXIN STABILIZED WITH TRYPTOPHAN OR TYROSINE | 2017 |
|
RU2741497C2 |
| BOTULINUM TOXIN CONTAINING COMPOSITION | 2017 |
|
RU2743746C2 |
| PROLONGED-RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING POLOXAMER | 2009 |
|
RU2482874C2 |
| METHODS OF TREATING CHRONIC NEUROGENIC INFLAMMATION BY MODIFIED CLOSTRIDIAL TOXIN | 2010 |
|
RU2568844C2 |
| COMPOSITIONS AND METHODS FOR IMPROVING DRUG THERAPY WITH METAL ION DEPENDANT AGENTS | 2010 |
|
RU2540520C2 |
| IMPROVED USE OF BOTULINUM NEUROTOXIN IN THE TREATMENT OF SIALORRHEA | 2018 |
|
RU2778481C2 |
| THERAPEUTIC AND COSMETIC USE OF SEROTYPE E NEUROTOXIN BOTULINUM | 2019 |
|
RU2800604C2 |
| CLOSTRIDIAL NEUROTOXINS WITH MODIFIED PERSISTENCE | 2009 |
|
RU2524429C2 |
| HIGH INTRODUCTION RATE OF NEUROTOXIC COMPONENT OF BOTULINUM TOXIN | 2007 |
|
RU2453333C2 |
| METHOD OF OBTAINING BOTULINUM NEUROTOXIN (VERSIONS) | 2010 |
|
RU2561459C2 |
